Also, we found that 98–100 % of all participants fulfilling the clinical trial or the AUR criteria also fulfilled the ABC criteria for full AD pathology including the required tau pathology, reassuring that the amyloid criterion reflects full AD in just about all cases. The gene discussed is MAPT; the disease is Alzheimer disease.